Pyridoxal kinase inhibition by artemisinins down-regulates inhibitory neurotransmission.
Level 5 - mechanism / opinion, no new human data
Bench research / structural biology, enzyme kinetics, and ex vivo slice electrophysiology
PubMed 33318193 · doi:10.1073/pnas.2008695117
What was done
Investigators determined the crystal structure of the metabolic enzyme pyridoxal kinase (PDXK) complexed with artesunate at 2.4-Å resolution. They evaluated PLP (vitamin B6) synthesis through enzyme kinetic assays, measured the activity of the PLP-dependent enzyme glutamic acid decarboxylase (GAD), and performed electrophysiological recordings in hippocampal brain slices to evaluate GABAergic signaling.
What was found
The crystal structure showed artesunate binding partially overlaps with the substrate pyridoxal binding site on PDXK, leading to inhibition of PLP biosynthesis. Artemisinins decreased GAD activity and presynaptically down-regulated GABAergic inhibitory neurotransmission in hippocampal slices. Beyond the 2.4-Å structural resolution, the abstract reports no specific numerical kinetic constants or effect magnitudes.
Why it matters
This study identifies PDXK as a direct target of artemisinin antimalarials, detailing a molecular mechanism whereby these drugs can suppress inhibitory GABAergic signaling in the central nervous system.
Limits
The study is entirely preclinical (crystallography, in vitro enzyme assays, and ex vivo slice electrophysiology) without in vivo animal behavioral or human clinical data. The abstract lacks specific quantitative metrics, such as inhibitory constants (Ki/IC50) or electrophysiological effect sizes, and does not establish whether standard clinical dosing reaches concentrations required for this inhibition.
Cited by
- supports Vitamin B6 is a required cofactor for converting glutamate into the inhibitory neurotransmitter GABA.